

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**愛 帝 宮 母 嬰 健 康 股 份 有 限 公 司**  
**AIDIGONG MATERNAL & CHILD HEALTH LIMITED**

*(Incorporated in Bermuda with limited liability)*

**(Stock code: 286)**

## **QUARTERLY UPDATE ON RESUMPTION PROGRESS**

This announcement is made by Aidigong Maternal & Child Health Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) pursuant to Rule 13.09 and 13.24A of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (“**Listing Rules**”) and the Inside Information Provisions (as defined in the Listing Rules) under Part XIVA of the Securities and Futures Ordinance (Chapter 571, Laws of Hong Kong).

References are made to the announcement of the Company dated 13, 19 March and 2 April 2025, (collectively, the “**Announcements**”) in relation to, among others, the guidance for the resumption of trading in the Shares set by the Stock Exchange (the “**Resumption Guidance**”). Unless otherwise defined or the context otherwise requires, capitalised terms in this announcement shall have the same meanings as those defined in the Announcements.

### **BUSINESS OPERATIONS**

The Group has continued business operations notwithstanding the suspension of trading in the Shares on the Stock Exchange.

## **UPDATE ON THE 2024 ANNUAL RESULTS**

As Ms. Zhu Yufei and Shenzhen Aidigong's chief financial officer still refused to cooperate and respond to and/or provide the necessary financial information on Shenzhen Aidigong and its subsidiaries to the Auditors for annual audit and preparation of the 2024 Annual Results purposes. The Group is consulting its professional advisers and expects it will take all necessary actions to protect its interests over Shenzhen Aidigong.

As such, the expected date of the publication of the 2024 Annual Results will need to be further agreed with the Auditor, and a separate announcement will be made by the Company as and when appropriate.

## **UPDATE ON PROGRESS OF RESUMPTION**

The Company is committed to working towards the resumption of trading in the Shares. The Company has been discussing the scope of the independent forensic investigation into the Matters and independent internal control review with the professional advisers. In addition, the Company has also been in discussions with professional advisers of the Group to explore and consider opportunities available to the Company in formulating a viable resumption proposal to address matters set out in the Resumption Guidance.

Further announcements will be made as and when appropriate should there be any material development on the Resumption Guidance.

## **CONTINUED SUSPENSION OF TRADING**

At the request of the Company, trading in the shares of the Company on the Stock Exchange has been suspended since 9:54 a.m. on 21 February 2025 and will remain suspended until further notice.

**Shareholders and potential investors of the Company should exercise caution when dealing in the securities of the Company.**

By Order of the Board  
**Aidigong Maternal & Child Health Limited**  
**Wong Wing Cheung**  
*Company Secretary*

Hong Kong, 20 May 2025

*As at the date of this announcement, the Board comprises Mr. Huang Wenhua, Mr. Lin Jiang, Mr. Li Runping and Ms. Meng Lijia as executive Directors; Mr. Lee Kar Lung as a non-executive Director; Mr. Shan Guoxin, Mr. Chu Pui Ki Dickson and Mr. Wang Bin as independent non-executive Directors.*